Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios

[1]  E. Romero-Sandoval,et al.  Potency and Therapeutic THC and CBD Ratios: U.S. Cannabis Markets Overshoot , 2022, Frontiers in Pharmacology.

[2]  M. Hellmich,et al.  Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Cognition, and Attention: A Double-Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers , 2020, Frontiers in Psychiatry.

[3]  M. di Forti,et al.  Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis. , 2020, Addiction.

[4]  V. Lorenzetti,et al.  'Standard THC Units': a proposal to standardise dose across all cannabis products and methods of administration. , 2020, Addiction.

[5]  P. Di Ciano,et al.  Sex differences in the acute effects of smoked cannabis: evidence from a human laboratory study of young adults , 2019, Psychopharmacology.

[6]  Steven Davenport.  Price and product variation in Washington's recreational cannabis market. , 2019, The International journal on drug policy.

[7]  Dominique Makowski,et al.  bayestestR: Describing Effects and their Uncertainty, Existence and Significance within the Bayesian Framework , 2019, J. Open Source Softw..

[8]  J. Ramaekers,et al.  Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition , 2019, Psychopharmacology.

[9]  R. Croft,et al.  A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects , 2019, European Archives of Psychiatry and Clinical Neuroscience.

[10]  C. Morgan,et al.  Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function , 2018, Translational Psychiatry.

[11]  P. McGuire,et al.  Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. , 2017, The American journal of psychiatry.

[12]  D. Nutt,et al.  Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis ‘amotivational’ hypotheses , 2016, Psychopharmacology.

[13]  G. Bedi,et al.  Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis , 2016, Neuropsychopharmacology.

[14]  R. Murray,et al.  The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial , 2016, Journal of psychopharmacology.

[15]  Paul J. Harrison,et al.  How Cannabis Causes Paranoia: Using the Intravenous Administration of ∆9-Tetrahydrocannabinol (THC) to Identify Key Cognitive Mechanisms Leading to Paranoia , 2014, Schizophrenia bulletin.

[16]  D. Bates,et al.  Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.

[17]  Nathalie A. Desrosiers,et al.  Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. , 2014, Clinical chemistry.

[18]  R. Murray,et al.  Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment , 2013, Journal of psychopharmacology.

[19]  Z. Atakan.  Cannabis, a complex plant: different compounds and different effects on individuals , 2012, Therapeutic advances in psychopharmacology.

[20]  Daniël Kleinloog,et al.  Does olanzapine inhibit the psychomimetic effects of Δ9-tetrahydrocannabinol? , 2012, Journal of psychopharmacology.

[21]  C. Morgan,et al.  Cognitive and subjective effects of mephedrone and factors influencing use of a 'new legal high'. , 2012, Addiction.

[22]  Stef van Buuren,et al.  MICE: Multivariate Imputation by Chained Equations in R , 2011 .

[23]  C. Morgan,et al.  Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study , 2010, British Journal of Psychiatry.

[24]  R. Murray,et al.  Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology , 2010, Neuropsychopharmacology.

[25]  O. Mason,et al.  The Psychotomimetic States Inventory (PSI): Measuring psychotic-type experiences from ketamine and cannabis , 2008, Schizophrenia Research.

[26]  C. Morgan,et al.  Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis , 2008, British Journal of Psychiatry.

[27]  Lineke Zuurman,et al.  Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. , 2006, Journal of pharmaceutical sciences.

[28]  Ralitza Gueorguieva,et al.  Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction , 2005, Biological Psychiatry.

[29]  Ralitza Gueorguieva,et al.  The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis , 2004, Neuropsychopharmacology.

[30]  J. Brandt.  The Hopkins Verbal Learning Test: Development of a new memory test with six equivalent forms. , 1991 .

[31]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.